Resources from the same session
LBA45 - Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)
Presenter: Ramon Salazar
Session: Proffered Paper session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
887O - First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with <sup>177</sup>Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial
Presenter: Eric Baudin
Session: Proffered Paper session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: NETs and endocrine tumours
Resources:
Slides
Webcast
1644O - Donafenib in locally advanced/metastatic, radioactive iodine-refractory, differentiated thyroid cancer: A randomized, double-blind, placebo-controlled, multi-center phase III clinical trial (DIRECTION)
Presenter: Yansong Lin
Session: Proffered Paper session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1645O - Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial
Presenter: Jaume Capdevila Castillon
Session: Proffered Paper session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 1644O and 1645O
Presenter: Marcia Brose
Session: Proffered Paper session: NETs and endocrine tumours
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: NETs and endocrine tumours
Resources:
Slides
Webcast